Biotech ABM That Converts Target Accounts Into Pipeline.

Your commercial team is targeting every biotech company in your CRM regardless of development stage. You send a partnership pitch to a company whose lead asset is in Phase I and two years from any commercial conversation. You send a commercial operations platform demo request to a company that just filed its BLA and is three months from launch with a completely different set of priorities. Both contacts ignore you because your outreach arrives at precisely the wrong moment in their cycle. Clinical-stage and commercial-stage biotech companies have entirely different mandates, budgets, and vendor urgency levels. A freshly funded Phase II oncology company is actively standing up its clinical infrastructure and has a newly unlocked budget and a VP of Clinical Operations who needs to make vendor decisions in the next 90 days. A company that commercialised two years ago has a procurement function, an approved vendor list, a legal review process, and a three-quarter renewal cycle it cannot deviate from. Reaching both with the same message at the same cadence is not just ineffective - it marks your company as one that does not understand how biotech businesses actually operate, and that reputation travels fast in a market where the same 40 people attend every major conference and talk to each other.

We tier your target accounts by development stage before a single message is sent: pre-clinical, Phase I, Phase II, Phase III, NDA or BLA submitted, and commercial launch. Each tier gets messaging calibrated to what that organisation is actually focused on right now. A Phase II company hears about preparing for the operational complexity of Phase III scale. A company with a regulatory submission pending hears about commercial readiness and the timelines ahead of them. A recently commercial company hears about optimising the infrastructure they built in a hurry before approval. You arrive with the right conversation at the right moment in each company's cycle, and you are never the vendor that asked a Phase I biotech about commercial launch pricing or pitched a CDMO partnership to a company that already filed with the FDA.

You have identified the Chief Scientific Officer as your primary contact at 50 target accounts and built your entire outreach sequence around that title. Your team sends 50 sequences and books three meetings in 60 days. What no one accounted for is the structural reality of how biotech organisations change as they grow. At a 40-person clinical-stage biotech, the CSO does own all external vendor decisions - there is no one else. At a 250-person company preparing for commercial launch, the CSO has not signed a vendor contract in two years. That decision now sits with a VP of Operations who joined from a commercial pharma background, a Head of Commercial who was hired specifically to build the go-to-market infrastructure, or a procurement committee that was formally established after the Series C closed and did not exist when the company was in Phase II. Meanwhile, the Licensing Director at a mid-size rare disease biotech holds all incoming co-development and partnership discussions, but your sequence never reached them because they do not carry a VP title and your list-building criteria filtered them out. At a gene therapy company running multiple IND filings simultaneously, the VP of Regulatory Affairs has more vendor decision authority than anyone with a commercial title because the regulatory pathway determines the entire programme budget. Same industry vertical, four entirely different buying structures, and none of them visible from a standard LinkedIn title search.

We map the buying committee at each target account individually before outreach begins. For each account we identify who actually holds the mandate for your vendor category at their specific development stage and headcount - whether that is a scientific leader, a business development executive, a commercial operations head, a Head of Regulatory Affairs, or a procurement function that was quietly established after the last funding round. We then build coordinated sequences that reach two to five relevant stakeholders per account simultaneously across email and LinkedIn so no decision-maker falls through the cracks and no single gatekeeper can block access to the full committee. Accounts where we identify a procurement function in addition to the functional buyer get a separate stakeholder thread that addresses vendor qualification criteria directly, because arriving at a procurement conversation without prior awareness of the product is a guaranteed dead end.

Your sales team sends an opening email referencing helping biotech companies accelerate their development timelines. The recipient - a VP of Business Development who has spent 12 years negotiating licensing agreements, managing CRO relationships, and sitting across the table from Big Pharma BD teams at Partnering meetings - reads the first line and closes the tab. The message could have been written for a medical device company, a diagnostics startup, or a contract research organisation. It does not reference their therapeutic area, their current development stage, their recent Phase IIb readout, their announced licensing deal from last quarter, their ClinicalTrials.gov listings, or any signal that suggests the sender has spent more than 30 seconds reviewing the company website. In a market where scientific credibility is the price of admission, and where a VP of BD at a clinical-stage biotech evaluates every inbound contact through the lens of whether this person understands drug development, a generic opening does not just get ignored. It actively signals that the sender is not operating in this market seriously, and that impression follows your company name in that contact's memory every time they see it at a conference, in a press release, or in a future email subject line.

We write account-specific opening sequences that reference each company's actual pipeline and current situation. A Phase IIb readout published last quarter and what it signals about that company's next 18 months. A partnership announcement with a large pharma that creates a specific gap in their vendor stack because the partner relationship covers some functions but not others. A ClinicalTrials.gov listing that reveals their trial design, the number of sites they are running, and the patient population complexity - all of which imply a specific operational need. A job posting for a Head of Clinical Operations that signals they are building internal capability in an area where your product is the alternative to a full-time hire. The goal is one opening sentence that makes the reader think you reviewed their pipeline before writing - not one that makes them think you pulled their domain from a database and hit send.

Your outbound programme runs on a fixed monthly cadence regardless of what is happening inside your target accounts or across the broader market. In January you reach a company two weeks before they announce a USD 150 million Series C that creates immediate procurement authority and active budget across six vendor categories simultaneously. You do not know the raise is coming, so the message lands generically, gets triaged to a later folder, and is forgotten before the wire transfer clears. In March you reach a different account three weeks after they reported a failed Phase III primary endpoint for their lead asset. The programme is in internal review, headcount is being assessed, leadership has changed, and no vendor conversation will happen for at least two quarters regardless of how good your outreach is. You send four follow-ups into silence wondering why no one is responding. Meanwhile, a competitor who runs clinical trial completion monitoring reached your highest-priority target account the week after their positive Phase II readout in a rare autoimmune indication - when budget had just been unlocked, the VP of Clinical Operations had a board-approved mandate to scale, and urgency was at its peak. That competitor is now in procurement review while you are still sending your fourth follow-up to the failed Phase III company.

We monitor funding announcements, clinical trial registration and completion updates on ClinicalTrials.gov, regulatory submission and approval filings, partnership and licensing announcements, and executive hiring events for every account in your target list throughout the programme. When a trigger event occurs we adjust messaging and reprioritise that account in the sequence queue within 48 hours of the announcement. Accounts with an active trigger - a new raise, a clean Phase II data package, a BLA filing, a new commercial hire - get moved to Tier 1 treatment and receive fully custom outreach that references the specific event and connects it directly to the operational need your product addresses. You reach accounts at the precise moment their mandate and budget are aligned rather than six weeks before or eight weeks after the window opened and closed.